1. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Issue 8 (August 2021) Authors: Wallis, Robert S; Ginindza, Sibuse; Beattie, Trevor; Arjun, Nishanee; Likoti, Morongwe; Edward, Vinodh A; Rassool, Mohammed; Ahmed, Khatija; Fielding, Katherine; Ahidjo, Bintou A; Vangu, Mboyo D T; Churchyard, Gavin Journal: Lancet Issue: Volume 9:Issue 8(2021) Page Start: 897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC 8711 Early biomarkers of lung inflammation and function in trials of host-directed tuberculosis therapies (TB-HDT). (24th April 2019) Authors: Wallis, Robert; Beattie, Trevor; Likoti, Morongwe; Ahidjo, Bintou; Edward, Vinodh; Rassool, Mohammed; Ahmed, Khatija; Ginindza, Sibuse; Fielding, Katherine; Churchyard, Gavin; Vangu, Mboyo Journal: BMJ global health Issue: Volume 4(2019)Supplement 3 Page Start: A15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Issue 6 (June 2020) Authors: Dooley, Kelly E; Savic, Radojkam; Gupte, Akshay; Marzinke, Mark A; Zhang, Nan; Edward, Vinodh A; Wolf, Lisa; Sebe, Modulakgotla; Likoti, Morongwe; Fyvie, Mark J; Shibambo, Innocent; Beattie, Trevor; Chaisson, Richard E; Churchyard, Gavin J Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗